This study is testing if tocilizumab can be safely given directly into the chest or belly of patients with advanced cancer that has caused fluid buildup (malignant pleural effusion or malignant ascites). Tocilizumab is an immunotherapy and targeted therapy. You would receive four weekly doses of tocilizumab through a catheter (a thin tube) already in place. Each dose will be slightly higher than the last. Researchers will watch for any side effects and see if the drug can be given successfully. This is a small study, planning to enroll 12 participants aged 18 to 89 years old. The study is currently recruiting patients.

Study design

This is an open-label, Phase 1 study where all 12 participants will receive tocilizumab, with the dose increasing each week. It is designed to see if the treatment is feasible and to identify any side effects.

What's involved

You would have four weekly infusions of tocilizumab, each lasting about an hour. You would also give a small blood sample before and after each treatment, and fluid drained from your body cavity will be collected for analysis. The total study duration is expected to be no more than 10 weeks.

Compensation

Not stated in the trial record.

Follow-up

The main safety and administration outcomes are measured at 6 weeks after the start of treatment. The total study duration is expected to be no more than 10 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.